Risk factors

T1 Energy faces mounting accumulated deficits, now totaling $1,093.1 million, driven by net losses of $367.8 million in 2025 and $450.6 million in 2024. The company is exposed to heavy financing obligations, including substantial indebtedness, preferred stock, and convertible notes. Manufacturing operations depend on leased facilities at G1_Dallas and G2_Austin, subject to landlord disruptions and construction risks. Regulatory and trade uncertainties, including Section 45X tax credits and tariff impacts, pose additional threats to profitability.

The Trust added operational risks around its new ether staking program, including third-party providers, slashing penalties, tax implications, and liquidity management.

Simplifies supplier references from CNH Industrial to CNH throughout the risk factors.

TJX added specific risks regarding geopolitical cybersecurity threats and M&A execution. Updates focus on digital marketing changes, labor costs, and trade tariffs.

TMC highlights regulatory uncertainties between ISA and US NOAA frameworks for seafloor nodule mining.

Cash fell to $88,000, making going-concern uncertainty and 12% convertible-note obligations central risks.

Company adopted a new TON treasury strategy, heavily exposing its financials, liquidity, and operations to Toncoin volatility.

Kartoon Studios faces substantial going concern doubts with $763.8 million in accumulated deficits and $2.9 million in cash.

The risk factors are dominated by XRP market volatility, regulatory classification risks, and cryptographic custody vulnerabilities.

The company faces severe dilution and stock issuance risks to convert debt and fund operations. Nasdaq listing compliance remains precarious following a recent deficiency notice. Wattbike acquisition concentration drives 71% of revenue.

Turn Therapeutics has a very limited operating history with only two full-time employees as of December 31, 2025. Financing agreements with GEM and Avenue create significant dilution and operating restrictions. The business depends entirely on successful clinical trials, third-party manufacturing, and FDA device clearances or drug approvals.

Tevogen faces severe liquidity constraints, relying on debt, stock sales, and grants for TVGN 489 development.